Pipeline

Ryvu Therapeutics is advancing a broad pipeline by addressing emerging targets in oncology.

Our pipeline includes candidates with differentiated therapeutic mechanisms, including programs directed at kinase, synthetic lethality, and immuno-oncology pathways.

Clinical Projects

  • Program/ Target Name
  • Indication
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Partner
  • Anticipated
    Milestones
  • RVU120
    CDK8/19
    • R/R AML/HR-MDS (RIVER-52) (monotheraphy)

    • Initial Ph II data in 4Q24

      ​

    • R/R AML (RIVER-81) (combination therapy)

    • Initial Ph II data in 4Q24

      ​

    • LR-MDS (REMARK) (monotherapy)

    • Initial Ph II data in 2Q25

    • Myelofibrosis (POTAMI-61) (monotherapy and combo)

    • Initial Ph II data in 2Q25

    • Solid Tumors (AMNYS-51)

    • Complete Ph I data
      & translational studies in 2024

      ​

  • MEN1703(SEL24
    PIM/FLT3
    • DLBCL (JASPIS-01)

    • Initiation of Ph II in 4Q24

      ​

Discovery & Preclinical Projects

  • Program/ Target Name
  • Indication
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Partner
  • Anticipated
    Milestones

Synthetic Lethality

  • RVU305 (PRMT5)
    • Solid tumors

    • IND/CTA submission
      in 2H25

  • WRN
    • Solid tumors

    • In lead optimization

  • NOVEL TARGETS
    • ONCOLOGY

Immuno-oncology

  • STING & MULTI-TARGET IMMUNE MODULATION COLLABORATION
    • ONCOLOGY
  • STING ADC
    • ONCOLOGY